company background image
DNA logo

Ginkgo Bioworks Holdings NYSE:DNA Stock Report

Last Price

US$1.16

Market Cap

US$2.2b

7D

1.8%

1Y

-5.7%

Updated

28 Mar, 2024

Data

Company Financials +

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA Stock Report

Market Cap: US$2.2b

DNA Stock Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States.

DNA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Ginkgo Bioworks Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ginkgo Bioworks Holdings
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$2.55
52 Week LowUS$1.03
Beta1.42
1 Month Change-24.18%
3 Month Change-31.36%
1 Year Change-5.69%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.54%

Recent News & Updates

Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Mar 01
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Recent updates

Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Mar 01
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Ginkgo Bioworks: More Awful Revenue Guidance

Mar 01

Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment

Jan 26

Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty

Dec 20

Ginkgo Bioworks: A Long Way To Go

Nov 21

News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Nov 13
News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Ginkgo Bioworks: More Revenue Issues

Nov 13

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Nov 10
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Porter's 5 Forces Suggest That Ginkgo Is A Buy

Oct 25

Ginkgo Bioworks: Products Progressing Towards Market

Oct 10

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

Aug 30

Ginkgo Bioworks: Lack Of Progress Is A Concern

Aug 18

Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)

Aug 10

Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds

Jun 23

Ginkgo Bioworks: Avoid For Now

Feb 20

Ginkgo: Standardizing Offerings For Growth

Feb 08

Ginkgo Bioworks: Increasing Focus On Pharma And Biotech

Jan 12

Ginkgo Bioworks launches Ginkgo Enzyme Services

Dec 08

Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals

Nov 11

Ginkgo, Draper develop new technologies to detect engineered DNA

Oct 17

Ginkgo stock rises on acquisition of French biotech Altar

Oct 04

Ginkgo Bioworks: Promising Upside But Not Without Risks

Sep 28

Ginkgo Bioworks: May The Ginkgo King Grow

Sep 13

Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?

Aug 26
Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?

Gingko Bioworks: Near-Term Challenges Trump Downstream Economics

Aug 17

Ginkgo Bioworks: Time To Buy

Aug 10

Biotech Zymergen surges 21% on $300M buyout deal with Ginkgo

Jul 25

Shareholder Returns

DNAUS ChemicalsUS Market
7D1.8%0.8%0.2%
1Y-5.7%14.6%28.1%

Return vs Industry: DNA underperformed the US Chemicals industry which returned 15.1% over the past year.

Return vs Market: DNA underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is DNA's price volatile compared to industry and market?
DNA volatility
DNA Average Weekly Movement11.6%
Chemicals Industry Average Movement5.2%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: DNA's share price has been volatile over the past 3 months.

Volatility Over Time: DNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20081,218Jason Kellyhttps://www.ginkgobioworks.com

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Ginkgo Bioworks Holdings, Inc. Fundamentals Summary

How do Ginkgo Bioworks Holdings's earnings and revenue compare to its market cap?
DNA fundamental statistics
Market capUS$2.20b
Earnings (TTM)-US$892.87m
Revenue (TTM)US$251.46m

9.2x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DNA income statement (TTM)
RevenueUS$251.46m
Cost of RevenueUS$54.01m
Gross ProfitUS$197.45m
Other ExpensesUS$1.09b
Earnings-US$892.87m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin78.52%
Net Profit Margin-355.08%
Debt/Equity Ratio0%

How did DNA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.